Current Neuro-Oncology

Volume 28 Number 3
31 January 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 3, 31 January

Kashiwagi H, Wanibuchi M, Ikeda N, Nonoguchi N, Furuse M, Kawabata S, Nihei K, Hu N, Akita K, Ono K, Miyatake SI.
Investigator-led clinical trial of boron neutron capture therapy system for recurrent high-grade meningiomas after radiation therapy: Randomized phase II study.
Neuro Oncol. 2026 Jan 21:noaf279. doi: 10.1093/neuonc/noaf279. PMID: 41560342. Trial registration ID: Unidentified˰ ˍ

Patel SH, Mayorov S, Kim W, Singh K, Loftus JR, Patrie JT, Batchala PP, Ko A, Lee MD, Jain R, Schiff D.
Magnetic resonance imaging features differentiate histologic and molecular subtypes of glioblastoma IDH-Wild type CNS WHO grade 4.
J Neurooncol. 2026 Jan 21;176(3):177. doi: 10.1007/s11060-026-05431-8. PMID: 41563605. ˍ

Nielsen SH, Tabari S, Skjøth-Rasmussen J, Jensdottir M, Urup T, Hansen AE, Bartek J, Rasmussen R.
Laser interstitial thermal therapy for IDH wild-type recurrent glioblastoma: a Scandinavian two-center cohort study.
Acta Neurochir (Wien). 2026 Jan 23;168(1):22. doi: 10.1007/s00701-026-06771-0. PMID: 41575548. ˍ

Ozer BH, Cohen AL, Colman H, Penas-Prado M, de Groot J, Loghin ME, Pan E, Raizer JJ, Kumthekar P, Fink KL, Walbert T, Merrell RT, Groves MD, Ahluwalia MS, Wu J, Burton EC, Vera E, Mendoza T, Grajkowska E, Wall K, Reyes J, Yuan Y, Armstrong TS, Gilbert MR.
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.
Neurooncol Adv. 2026 Jan 23;8(1):vdaf261. doi: 10.1093/noajnl/vdaf261. PMID: 42028236. Trial registration ID: NCT01931098. ˍ

Teo T, Karanjia J, Wabnitz P, Kichenadasse G, Gan HK, Cooper A, Fuller D, Noll B, Zhou Y, Wei L, Wang H, Liu J, Zhou X, Wang K, Wang S.
A phase I/IIa study of auceliciclib in patients with advanced solid tumours and in combination with temozolomide in patients with recurrent/relapsed high-grade glioma.
ESMO Open. 2026 Jan 24;11(2):106035. doi: 10.1016/j.esmoop.2025.106035. PMID: 41581338. Trial registration ID: ACTRN12621000479808. ˍ

Peng F, Koh WY, Lee CY.
Frontal glioblastoma masquerading as schizophrenia exacerbation.
Oxf Med Case Reports. 2026 Jan 25;2026(1):omaf291. doi: 10.1093/omcr/omaf291. PMID: 41589101. ˍ

Slater JM, Horick NK, Nachtigall LB, Parsons MW, Tritos NA, Faje AT, Dietrich J, Fullerton B, Sherman JC, Curry WT, Arrillaga-Romany IC, Cahill DP, Nahed BV, Wang IS, Botticello TM, Oh KS, Yeap BY, Shih HA.
Cognitive Function, Quality of Life, and Survival Outcomes in Patients with Lower Grade Gliomas Treated with Proton Radiation Therapy: A Phase II study.
Neuro Oncol. 2026 Jan 25:noag008. doi: 10.1093/neuonc/noag008. PMID: 41581137. Trial registration ID: Unidentified˰ ˍ

Furman O, Falah E, Dvir I, Satra-Shenes O, Bittan A, Bokstein F, Blumenthal DT, Taliansky A, Zach L.
Rethinking treatment de-escalation in elderly glioblastoma: Lessons from a multicenter real-world cohort.
Neurooncol Adv. 2026 Jan 27;8(1):vdag014. doi: 10.1093/noajnl/vdag014. PMID: 41778155. ˍ

Piha-Paul SA, De La Fuente M, Iwamoto F, Zhu JJ, Nagpal S, Braiteh F, Chandra S, Fu Y, Chen C, Yang Z, Tsai KK.
Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion.
ESMO Open. 2026 Jan 27;11(2):106047. doi: 10.1016/j.esmoop.2025.106047. PMID: 41604813. Trial registration ID: NCT04190628. ˍ

Singh J, Bhardwaj S, Singh S, Mansoori S, Vasant S, Srivastava K, Kedia S, Garg A, Suri A, Sharma MC, Sarkar C, Suri V.
Pediatric and Adolescent/Young Adult High-Grade Gliomas With Adult-Type Molecular Features.
Pathol Int. 2026 Jan 27;76(1):e70087. doi: 10.1111/pin.70087. PMID: 41589343˰ ˍ

Dipasquale A, Giordano P, Bosio A, Wijnenga MMJ, Giordano L, Losurdo A, Persico P, Padovan M, Viggiano A, Catapano G, Geurts M, Pessina F, Santoro A, Lombardi G, Simonelli M.
Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.
J Neurooncol. 2026 Jan 28;176(3):186. doi: 10.1007/s11060-026-05439-0. PMID: 41604034˰ ˍ

Dixit KS, Kumthekar P, Lukas RV, Williams A, Tate MC, Chandler JP, Jamshidi P, Helenowski I, Zhang H, Bloch O, Raizer JJ.
A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.
J Neurooncol. 2026 Jan 28;176(3):185. doi: 10.1007/s11060-026-05446-1. PMID: 41604000. Trial registration ID: NCT02794883˰ ˍ

Ene CI, Singh S, Venkataraman T, Phillips LM, Long JP, Singh D, Tran ND, Tufaro F, Anand PJ, Navin N, Prabhu S, Weinberg JS, Larman HB, Gomez-Manzano C, Fueyo J, Lang FF.
Systemic immune correlates of long-term survival after Delta-24-RGD based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET).
Clin Cancer Res. 2026 Jan 29. doi: 10.1158/1078-0432.CCR-25-3566. PMID: 41609523. Trial registration ID: NCT02197169˰ ˍ

Jia Z, Jiang T, Zhang Y, Chen Q, Di Z, Yuan Q, Qian K, Gan L, Ma C, Lin X.
Clinical Efficacy and Safety Assessment of Specific-Mode Electroacupuncture Stimulation Combined With Paclitaxel for Recurrent Malignant Gliomas: Study Protocol for a Single-Arm Trial.
JMIR Res Protoc. 2026 Jan 29;15:e84593. doi: 10.2196/84593. PMID: 41610368. Trial registration ID: NCT06818331. ˍ

Del Bene M, Caldiera V, Stanziano M, Carone G, Falanga A, Piccardi A, Simonetti G, Carozzi C, Frazzetta G, Silvani A, Prada F, Grisoli M, Ciceri E, DiMeco F.
Focused ultrasound for blood-brain barrier opening in brain tumor patients: Technical nuances.
Neurooncol Adv. 2026 Jan 31;8(1):vdag020. doi: 10.1093/noajnl/vdag020. PMID: 41821761. ˍ